$900-Million Biopharmaceutical Park Planned for Shenzhen
ePT--the Electronic Newsletter of Pharmaceutical Technology
The Shenzhen government is planning to build a new national biopharmaceutical park in the Shenzhen Grand Industrial Zone.
The city government in Shenzhen in southern China's Guangdong province is planning to build a 2.92-mile2 national biopharmaceutical park in the Shenzhen Grand Industrial Zone.
The center will be designed for biopharmaceutical research and development and will house businesses in the biomedical engineering, marine biotechnology, biopharmaceuticals, modern Traditional Chinese Medicines, and chemical drugs industries.
The RMB 7.2-billion (USD 900-million) project will be funded by government and nongovernmental organizations and is subject to approval by China's National Development and Reform Commission (NDRC). The base is expected to have annual revenues of RMB 100 billion (USD 12.5 million).
The NDRC also has approved two other biopharmaceutical bases in Changchun (Jilin province) and Shijiazhuang (Hebei province).
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
